Merck (MRK) Free Cash Flow (2009 - 2026)
Merck (MRK) posted quarterly Free Cash Flow of $2.9 billion for Q1 2026, up 149.74% year-over-year from $1.2 billion in Q1 2025, and up 60.47% quarter-over-quarter from $1.8 billion in Q4 2025.
Merck (MRK) Free Cash Flow (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Free Cash Flow for 18 consecutive years, with $2.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 149.74% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $14.1 billion (down 17.16% YoY), while the FY2025 annual figure was $12.4 billion, down 31.7% from the prior year.
- Free Cash Flow rose to $2.9 billion in Q1 2026 per MRK's latest filing, from $1.8 billion in the prior quarter.
- Across five years, Free Cash Flow topped out at $8.5 billion in Q3 2024 and bottomed at -$743.0 million in Q4 2023.
- Historically, Free Cash Flow has averaged $3.4 billion across 5 years, with a median of $2.9 billion in 2026.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 2290.51% — and 2023, when it slumped 122.65%.
- Merck's Free Cash Flow stood at $3.3 billion in 2022, then plunged by 122.65% to -$743.0 million in 2023, then surged by 438.22% to $2.5 billion in 2024, then retreated by 27.42% to $1.8 billion in 2025, then soared by 60.47% to $2.9 billion in 2026.
- Business Quant data shows MRK's Free Cash Flow at $2.9 billion in Q1 2026, $1.8 billion in Q4 2025, and $6.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.48 Bn |
| Jun 30, 2026 | 4.48 Bn |
| Mar 31, 2026 | 2.93 Bn |
| Mar 31, 2026 | 2.93 Bn |
| Dec 31, 2025 | 1.82 Bn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 6.84 Bn |
| Sep 30, 2025 | 6.84 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Mar 31, 2025 | 1.17 Bn |
| Mar 31, 2025 | 1.17 Bn |
| Dec 31, 2024 | 2.51 Bn |
| Dec 31, 2024 | 2.51 Bn |
| Sep 30, 2024 | 8.51 Bn |
| Sep 30, 2024 | 8.51 Bn |
| Jun 30, 2024 | 4.85 Bn |
| Jun 30, 2024 | 4.85 Bn |
| Mar 31, 2024 | 2.23 Bn |
| Mar 31, 2024 | 2.23 Bn |